Document:

Exhibit 10.1

 

ASSET
TRANSFER AGREEMENT

 

 

 

JANUARY
1, 2020

 

 

    	1 

    	 

    

ASSET
TRANSFER AGREEMENT

 

This
ASSET TRANSFER AGREEMENT (the “Agreement”) is entered into as of January 1, 2020 (“Execution Date”)
by and between:

 

		(1)	8K
                                         Miles Software Services Inc., a Nevada corporation, having its registered office
                                         at 4309 Hacienda Drive, Suite 150, Pleasanton, CA 94588 (the “Seller”
                                         which expression shall unless repugnant to the context or meaning thereof, mean and include
                                         its successors and administrators); and

 

		(2)	Healthcare
                                         Triangle Inc., a Nevada corporation, having its principal office at 4309 Hacienda
                                         Drive, Suite 150, Pleasanton, CA 94588 (hereinafter referred to as the “Purchaser”
                                         which expression shall unless repugnant to the context or meaning thereof, mean and include
                                         its successors and administrators).

 

(The
Seller and the Purchaser are individually referred to in this Agreement as a “Party” and together as the “Parties”).

 

RECITALS:

 

 

WHEREAS:
the Seller is a leading global information technology business transformation, secure cloud solutions
and managed services provider headquartered in the San Francisco Bay Area providing solutions – SMAC (Social, Mobile,
Analytics and Cloud) for seamless connectivity between consumers, small and mid-size enterprises, large enterprises, healthcare
providers and pharmaceutical companies (the “Business”);

 

WHEREAS:
The Seller wishes to sell, transfer, convey and assign to the Purchaser, and the Purchaser wishes to purchase from the Seller
the business, assets, intellectual property and operations relating to healthcare
and life sciences domain that currently form part of the Seller’s Business (the “Transferred Assets”),
as a whole and as a going concern in exchange for the issuance by the Purchaser to the Seller of 25,500,000 shares of the Purchaser’s
Common Stock, on and subject to the terms and subject to the conditions specified in this Agreement (the “Purchaser Equity”).

 

WHEREAS:
The Purchaser and Seller have passed appropriate board resolutions authorizing the execution, delivery and performance of
this Agreement and the transactions contemplated hereby and authorizing their respective representatives to execute all documentation
and undertake all actions in relation thereto; and

 

WHEREAS:
The Seller and the Purchaser wish to record in this Agreement the terms of the proposed transfer of the Transferred Assets
in consideration for the issuance of the Purchaser Equity by the Purchaser to the Seller.

 

AGREEMENT:

    	2 

    	 

    

NOW
THEREFORE, THE PARTIES AGREE AS FOLLOWS:

 

		1.	AGREEMENT
                                         TO SELL AND PURCHASE

 

1.1 
Subject to the other provisions of this Agreement, the Seller hereby sells, conveys, transfers and assigns the Transferred Assets
to the Purchaser, as a whole, and as a going concern, in consideration for the issuance to the Seller of the Purchaser Equity,
in the manner and on the terms specified in this Agreement.

 

1.2 
Subject to the other provisions of this Agreement, and based on the representations of the Seller contained in this Agreement
(“Representations”), the Purchaser hereby purchases from the Seller the Transferred Assets in consideration
for the issuance to the Seller of the Purchaser Equity, in the manner and on the terms specified in this Agreement.

 

1.3 
Without prejudice to the generality of the foregoing, and subject to Clause 1.4 below, the term “Transferred Assets”
as used in this Agreement shall include all assets of the Business involved in healthcare and life sciences domain, including,
without limitation, each of the following:

 

(i) 
All assets (moveable, immoveable, tangible or
intangible) owned by the Seller used for or in connection with the Transferred Assets, including the tangible assets identified
in Schedule 1.3(i): Transferred Tangible Assets to this Agreement (collectively, the “Transferred Tangible Assets”),
free and clear of any liens, pledges, charges, mortgages, defects in title, objections, security interests, claims, options, rights
of first offer or refusal, hypothecations, restrictions on transfer, or other encumbrances of any kind (“Encumbrances”)

 

(ii) 
all immigration-related interests, obligations
and liabilities of the Seller as the original petitioning employer, including but not limited to those obligations, liabilities,
and undertakings arising from and under attestations contained in the Labor Condition Applications (LCAs) filed with the U.S.
Department of Labor for H-1B petitions filed by the Seller;

 

(iii) 
All agreements, contracts, franchises, insurance
policies, leases, property licenses, purchase orders, software licenses, software escrow agreements, technology licenses understandings,
or arrangements relating to the Seller’s healthcare and life sciences business (“Arrangements”) entered
into by the Seller for or in connection with the Seller’s healthcare and life sciences business (“Transferred Contracts”)
and listed and identified in Schedule 1.3(iii): Transferred Contracts to this Agreement;

 

(iv) 
Subject to obtaining approvals of any third parties
as may be required, all Arrangements entered into by the Seller for or in connection with the Seller’s healthcare and life
sciences business (“Future Transferred Contracts”) and listed and identified in

    	3 

    	 

    

Schedule
1.3(iv):: Future Transferred Contracts to this Agreement, which Future Transferred Contracts shall be deemed assigned automatically
and immediately upon receipt of the appropriate approvals of any third parties, as required;

 

(v) 
All government and regulatory permits, licenses,
concessions, or other similar consents held by the Seller for or in connection with the Seller’s healthcare and life sciences
business (“Permits”), if and to the extent such Permits are valid and subsisting on the Closing Date and are
capable of being transferred or assigned in accordance with applicable law, as listed and identified in Schedule 1.3(v): Permits
to this Agreement;

 

(vi) 
The release from employment by the Seller of
the employees connected with the Seller’s healthcare and life sciences business, who have been offered employment by the
Purchaser as on the Closing Date, who have accepted such employment, and who are identified in Schedule 1.3(vi): Transferred
Employees to this Agreement (“Transferred Employees”);

 

(vii) 
All goodwill, intellectual property and knowhow
connected with or relating to the Seller’s healthcare and life sciences business, including all brands, registered or unregistered
trademarks and service marks, domain names and web-pages of the Seller’s healthcare and life sciences business, copyright
therein, and all other information, relationships, processes, methods, templates, networks, databases (including of customers
and suppliers), and any other intellectual property rights, goodwill, knowhow and information (whether proprietary, confidential
or otherwise) used for or in connection with the Seller’s healthcare and life sciences business (“Knowhow, IP and
Goodwill”), including the Knowhow, IP and Goodwill identified in Schedule 1.3(vii): Knowhow, IP and Goodwill
to this Agreement; and

 

(viii) 
All business and financial records and documents
connected with or relating to the Seller’s healthcare and life sciences business, including vouchers, invoices, books of
accounts, tax records, tax returns, notices, filings, and all other documents and records (whether proprietary, confidential or
otherwise) used for or in connected with the Seller’s healthcare and life sciences business (“Business Records”),
owned, or controlled by the Seller or its agents, including any tax advisors, accountants, auditors or legal advisors.

 

1.4 
Notwithstanding anything contained in any other provision of this Agreement, the Seller’s healthcare and life sciences business
specifically and expressly excludes any and all libilities and obligations associated with the Seller’s Business and outstanding
on the date hereof, other than those listed on Schedule 1.4: Transferred Liabilities.

 

		2.	CONSIDERATION

 

In
consideration for the sale, transfer, assignment and conveyance of the Transferred Assets by the Seller, in accordance with the
provisions hereof, the Purchaser shall issue to the Seller the

    	4 

    	 

    

Purchaser
Equity pursuant to a Common Stock Purchase Agreement, in substantially the form attached as Exhibit A hereto.

 

		3.	TAX
                                         MATTERS AND OTHER COSTS

 

3.1 
The Purchaser shall issue the Purchaser Equity to the Seller, in accordance with Clause 2 of this Agreement, for a transfer
of the Transferred Assets, as a whole and on a going concern basis only, and accordingly the Parties agree that no goods and services
tax, sales tax or customs duty or similar tax, or surcharge thereon shall be payable by the Purchaser to the Seller in connection
with the sale of the Transferred Assets. If any goods and services tax, sales tax or customs duty or similar tax, or surcharge
thereon is payable on the sale of the Transferred Assets, then such tax (other than any tax on the Seller’s income or the
Seller’s capital gains) shall be borne by the Seller.

 

3.2 
Where any tax is required to be withheld or deducted at source on any payment by any Party pursuant to this Agreement, the payor
shall be entitled to withhold or deduct the same at source, as required by law, provided that the payor shall issue the recipient
thereof with necessary certificates of such withholding or deduction at source in accordance with applicable law, and within the
time periods stipulated.

 

3.3 
The Seller shall bear all income and capital gains taxes payable by the Seller on account of the sale of the Transferred Assets
pursuant to this Agreement.

 

3.4 
The Purchaser shall bear the applicable taxes levied by any authorities whatsoever payable in connection with any deed or document
required to be executed in relation to the conveyance or assignment, as the case may be, of any property included in the Transferred
Assets.

 

3.5 
Each Party shall bear the costs and charges of its own professional and legal advisors.

 

		4.	CLOSING

 

4.1 
Closing shall take place at the Seller’s place of business on January 1, 2020, at 5:00 pm PST.

 

4.2 
At Closing, the Seller shall execute and deliver the Assignment Deed, in substantially the form attached as Exhibit B
hereto.

 

4.3 
At Closing, the Parties shall complete each of the actions and steps required to complete the sale of the Transferred v from the
Seller to the Purchaser and the issuance of Purchaser Equity to Seller.

    	5 

    	 

    

		5.	REPRESENTATIONS
                                         AND WARRANTIES

 

		5.1	Each
                                         Party represents and warrants to the other as follows.

 

(i) 
It has all requisite power and authority to enter
into and perform all its obligations under this Agreement.

 

(ii) 
It has taken all actions, obtained all regulatory,
corporate and contractual authorizations, and submitted all notices or filings required to be submitted, for it to validly enter
into this Agreement and perform all its obligations under this Agreement.

 

(iii) 
The execution and delivery of, or the performance
of obligations under, this Agreement do not violate or conflict with any statute, rule, regulation, directive, other law, judgment,
order, decree or award applicable to it or to any provision of its constituent documents, or any agreement, contract, promise,
covenant, undertaking, representation or warranty, applicable to or made by it.

 

(iv) 
This Agreement constitutes legal, valid and binding
obligations, enforceable against it in accordance with its terms.

 

5.2 
The Seller hereby represents to the Purchaser, that to the best of its knowledge, each of the Representations set out in Schedule
5.2: Representations to this Agreement is true, materially accurate, and not misleading, as on the date of this Agreement
and as on the Closing Date. Provided that such Representations are made subject to the following:

 

(i) 
The Representations are qualified to the extent
such qualifications have been expressly set out in the disclosure schedule set out in Disclosure Schedule to this Agreement
(“Disclosure Schedule”), in substantially the form attached as Exhibit C hereto;

 

(ii) 
Where any Representation is stated to be made
to the Seller’s best knowledge, or where any Representation is similarly qualified, such Representation has been

 

(iii) 
made and shall be deemed to have been made after
the exercise of reasonable diligence by the Seller;

 

(iv) 
Any Representation made expressly as of a specific
date is true and correct as of that specific date only;

 

(v) 
Any Representation that addresses any specific
circumstances or facts does not allow recourse to a general statement;

 

(vi) 
Each Representation is separate and independent
and, save as expressly provided to the contrary, shall not be limited by inference from any other Representation or any other
term of this Agreement.

    	6 

    	 

    

5.3 
The Seller shall not do, allow or procure to be done, any act or omission that would constitute a breach of any Representation,
or that would make any Representation false, incomplete, inaccurate or misleading if they were so given.

 

5.4 
The Seller covenants to disclose promptly to the Purchaser in writing, immediately upon becoming aware of the same, any matter,
event, or circumstance (including any omission to act) that may arise or become known between the date of this Agreement and the
Closing Date and that would render any Representation to be inaccurate or incomplete or that relate to the occurrence of any material
adverse event.

 

		6.	CONFIDENTIALITY

 

6.1 
For purposes of this Agreement, Confidential Information means all scientific, technical, trade, financial or business
information or materials that are either proprietary or not publicly known that any Party (Discloser) may from time to
time disclose or otherwise make available to the other Party (Recipient) in connection with or pursuant to this Agreement.
Without prejudice to the generality of the foregoing, Confidential Information includes the provisions of this Agreement, and
information and materials related to any activities of the Discloser whether or not such information is marked or identified as
confidential or proprietary. Provided that in relation to any and all Confidential Information connected in any manner with the
Transferred Assets, the Seller shall be deemed the Discloser of such Confidential Information prior to the Closing Date, and the
Purchaser shall be deemed the Discloser of such Confidential Information after the Closing Date (notwithstanding the earlier disclosure
of such information by the Seller to the Purchaser).

 

6.2 
Notwithstanding anything contained in Clause 6.1, Confidential Information shall not include information that:

 

(i) 
at the time of disclosure, is known publicly
or thereafter becomes known publicly through no fault attributable to the Recipient;

 

(ii) 
becomes available to the Recipient from a third
party that is not legally prohibited from disclosing such information, provided such information was not acquired from the Discloser;

 

(iii) 
was developed by the Recipient independently
of information obtained from the Discloser, as shown by the Recipient’s written records that predate the receipt of such
information from the Discloser;

 

(iv) 
was already known to the Recipient before receipt
from the Discloser, as shown by the Recipient’s written records that predate the receipt of such information from the Discloser;
or

 

 (v) is released with the prior written consent of the Discloser.

 

    	7 

    	 

    

6.3 
A disclosure of Confidential Information made by or on behalf of the Discloser, including by its employees, agents, consultants,
affiliates or associates, as well as disclosure by any means (whether written or oral) or through any medium, and any disclosure
made prior or subsequent to the date of this Agreement shall be deemed to be a disclosure of Confidential Information for purposes
of this Agreement.

 

6.4 
Each Discloser hereby represents, warrants and covenants that it is entitled to and will be entitled to disclose all Confidential
Information disclosed pursuant to or in connection with this Agreement.

 

6.5
The Recipient hereby covenants to do each of the following for a period of two (2)  years following the earlier
of (a) the Closing Date or (b) the expiry or termination of this Agreement for any reason:

 

(i) 
Keep all Confidential Information in strict confidence,
with at least the same level of care as it applies to keeping its own personal, financial or proprietary information confidential,
and in any event no less than reasonable care to prevent the unauthorized disclosure or use of any Confidential Information;

 

(ii) 
Not use, modify, create any derivative works
from, or otherwise deal in any Confidential Information, except when the Recipient is required to do so solely in connection with
this Agreement, and then only as specified by the Discloser;

 

(iii) 
Not disclose any Confidential Information to
any other persons or entities except persons who need access to the Confidential Information in connection with this Agreement,
and who are bound by equivalent obligations of confidentiality; and

 

(iv) 
Notify the Discloser in writing immediately upon
discovery of any unauthorized use or disclosure of any Confidential Information and reasonably cooperate with the Discloser to
prevent any unauthorized disclosure or use of the Confidential Information and to mitigate any losses arising from such unauthorized
disclosure or use.

 

Provided
that if the Recipient is required to disclose any Confidential Information by reason of a legal requirement or by the order of
a judicial or administrative authority or by the listing requirements of a recognized stock exchange on which the securities of
the Recipient are publicly traded, the Recipient, to the extent reasonably practicable, shall send to the Discloser prior notice
of such requirement in order to allow the Discloser reasonable opportunity to oppose such process or to obtain protective or confidential
treatment of the Confidential Information, and to the extent that a protective order or other legal protection is not obtained
by the Discloser, the Recipient shall disclose only that portion of the information that is legally required to be disclosed.

 

6.6 
Subject to the other provisions of this Clause 6, the Recipient shall be liable for any breach of its covenants in Clause
6.5 by any person to whom any Confidential Information

    	8 

    	 

    

is
disclosed or provided by the Recipient, and the Recipient undertakes to take any and all necessary actions, at its own cost and
expense, to prevent or remedy such breach.

 

6.7 
Upon expiration or termination of this Agreement or earlier upon receipt of a written request from the Discloser, the Recipient
shall cease all use of the Confidential Information and promptly return to the Discloser all documents and materials of the Discloser
that relate to or contain any Confidential Information without retaining copies thereof, except for one (1) copy that may be made
and retained by the Recipient solely for record-keeping and purposes of assuring continued compliance with its obligations under
this Agreement.

 

6.8 
Unless otherwise expressly provided in this Agreement, the disclosure of Confidential Information shall not of itself grant the
Recipient any right, title or interest in the Confidential Information, except the limited right to use the Confidential Information
solely for the purposes specified pursuant to and in accordance with this Agreement.

 

6.9 
The Recipient acknowledges and agrees that the Discloser is not making and shall not be deemed to have made any implied representations
or warranties regarding the accuracy or completeness of any Confidential Information,
but nothing contained in this Clause 6 shall affect any Representation or any other express representation or warranty
made with regard to the accuracy or completeness of any Confidential Information.

 

6.10 
The Parties agree that in addition to any other rights or remedies available under this Agreement, in the event of any breach
or any threatened breach of any obligations under this Clause 6 where such breach
or threatened breach is in any way attributable to the Recipient, monetary damages do not provide a sufficient remedy,
and the Discloser shall be entitled to an injunction restraining and to seek specific performance by the Recipient of any obligation
under this Clause 6.

 

		7.	INDEMNIFICATION

 

7.1 
Subject to the other provisions of this Clause 7, from and after the Closing, the Seller shall indemnify the Purchaser
and save and hold the Purchaser harmless against any and all judgments, awards, liabilities, losses, costs or damages, including
reasonable fees and expenses of attorneys, accountants and other professional advisors, actually incurred, whether involving a
dispute solely among the Parties or otherwise, and any costs, including reasonable fees and expenses of attorneys, accountants
and other professional advisors, incurred in investigating, defending or settling any claim, action or cause of action (“Losses”)
suffered, incurred or paid, directly or indirectly, by any of them as a result of, arising out of or related to any third party
claims made against the Purchaser as a result of:

 

(i) 
any failure of any Representation of the Seller,
in each case as qualified and modified by the relevant Disclosure Letter, to be true and correct in all material respects, in
accordance with the provisions hereof; and/or

    	9 

    	 

    

 (ii) any breach of any covenant by the Seller in this Agreement.

 

7.2 
The Representations contained in this Agreement, including the Disclosure Schedule and any document delivered pursuant to this
Agreement, shall survive Closing until the date that is twenty-four (24) months after the Closing Date.

 

		8.	TERMINATION

 

This
Agreement may not be terminated except by mutual consent of the Parties recorded in writing and then only on such terms as shall
be recorded.

 

		9.	MISCELLANEOUS

 

9.1 
The section and clause headings and captions used in this Agreement are for convenience and identification only; otherwise, they
form no part of this Agreement and do not affect its interpretation or construction.

 

9.2 
References to sections, clauses or schedules without further specification are references to sections and clauses of this Agreement.

 

9.3 
References to this Agreement include all sections, clauses and schedules in this Agreement and all recitals to this Agreement,
as amended from time to time in writing by the Parties in accordance with the provisions of this Agreement.

 

9.4 
Any reference to a statute or any provision of a statute includes a reference to that statute or provision and any rule, regulation,
notification, circular, or direction made or issued pursuant to that statute or provision, as may be from time to time modified
or re-enacted, whether prior to or after the date of this Agreement.

 

 9.5 References to the singular include references to the plural and vice versa.

 

9.6 
Words denoting one grammatical gender include references to all grammatical genders.

 

9.7 
When the term “include”, “including” or “including in particular” is used in this Agreement,
such use means “include without limitation”, “including without limitation” and “including in particular
and without limitation” respectively.

 

9.8 
The laws of the State in California shall govern all matters arising out of or relating to this Agreement, including, its validity,
interpretation, construction, performance, expiry, termination and enforcement.

 

9.9 
Any controversy, claim, or dispute arising out of or in connection with this Agreement, including any question regarding its existence,
validity or termination, shall be settled by arbitration administered by the American Arbitration Association in accordance

    	10 

    	 

    

with
its arbitration rules, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.
A notice of, or request for, arbitration will not operate to stay, postpone or rescind the effectiveness of any demand for performance.

 

9.10 
Subject to the provisions of Clause 9.9, the Parties hereby confirm that the courts in Alameda County, California have
jurisdiction over the Parties in connection with this Agreement.

 

9.11 
Any notice, communication, document or other instrument required to be given under this Agreement shall be in writing and given
by sending it by recognized courier with acknowledgement of receipt requested, or by electronic mail to the addresses specified
below, or such other addresses as have been previously notified by each Party to the other in accordance with the provisions of
this Clause 9.11.

 

 

IF
TO THE PURCHASER:

 

HEALTHCARE
TRIANGLE INC.

 

Address:
4309 Hacienda Drive, Suite 150

Pleasanton,
CA 94588

 

Attn:
Suresh Venkatachari Tel.: 781-354-0843

Email:
sureshv@healthcaretriangle.com

 

 

IF
TO THE SELLER:

 

8K
MILES SOFTWARE SERVICES INC.

 

Address:
4309 Hacienda Drive, Suite 150

Pleasanton,
CA 94588

 

Attn:
Lakshmanan Kannappan Tel.: 408-605-7548

Email:
lkannappan@8kmiles.com

 

9.12 
Any notice, direction or other instrument required or permitted to be given under this Agreement shall be deemed to have been
validly and effectively given (i) if sent by recognized courier with acknowledgement of receipt requested, then on the date of
such delivery or receipt if such date is a working day in the city where the recipient’s address is located or otherwise
on the next working day, or (ii) if transmitted by electronic mail, then on the working day (in the city where the recipient’s
address is located) following the date of transmission.

    	11 

    	 

    

9.13 
This Agreement contains all the promises, agreements, conditions and understandings between the Parties with respect to the subject
matter of this Agreement, and supersedes all prior or contemporaneous promises, agreements, conditions and understandings, whether
oral or written, with respect to such subject matter.

 

9.14 
Each Party agrees to execute and deliver all further instruments and documents and to perform all other acts that may be reasonably
necessary or expedient to further the purposes of this Agreement. Each Party will not, directly or indirectly, permit or condone
any action or engage in any omission or inaction that might cause any undertaking or covenant, or any representation or warranty
not to be satisfied or fulfilled, including any action or inaction that might cause any undertaking, covenant, representation
or warranty not to be true, correct and accurate during the term of or the term required under this Agreement.

 

9.15 
This Agreement may be executed in one or more counterparts, all of which together shall constitute one and the same instrument.
Any Party may enter into this Agreement by executing a counterpart, and a delivery by email to the other Party of a scanned copy
of any such executed counterpart shall be deemed to constitute delivery of the original counterpart.

 

9.16 
No amendment of, supplement to or suspension of this Agreement shall be effective unless it is in writing and duly executed by
both Parties.

 

9.17 
No Party, without the prior written consent of the other Party, may assign to any other person any of its rights, or delegate
or sub-contract to any other person, the performance of any of its obligations arising under or related to this Agreement.

 

9.18 
This Agreement binds and benefits the successors and permitted assigns of each Party. Without prejudice to the foregoing, this
Agreement does not confer any enforceable rights or remedies upon any person other than the Parties.

 

9.19 
Nothing in this Agreement shall or shall be deemed to constitute a partnership between the Parties or to constitute any Party
as the agent of the other Party for any purpose.

 

9.20 
A Party shall not make or publish any announcement or press release concerning or
connected with this Agreement, without the prior written consent of the other Party, unless otherwise required by law.

 

9.21 
No provision of this Agreement shall be construed against a Party on the ground that it or its agents or advisors drafted such
provision.

 

9.22 
If any provision of this Agreement should be or become entirely or partly invalid or unenforceable, such invalidity or unenforceability
shall not affect the validity or enforceability of any other provision of this Agreement. Any invalid or unenforceable provision
shall be regarded as replaced by such valid and enforceable provision that as closely

    	12 

    	 

    

as
possible reflects the economic purpose that the Parties hereto had pursued with the invalid or unenforceable provision.

 

 

 

 

[The
remainder of this page has been deliberately left blank. The signature page and schedules follow]

    	13 

    	 

    

IN
WITNESS WHEREOF, the Parties have executed and delivered this Agreement effective as of the day and year first written above.

 

 

 

SELLER:

 

8KMILESSOFTWARESERVICES,
INC.

 

By:
/s/ Lakshmanan Kannappan

Name:
Lakshmanan Kannappan

Title: Chief Operating Officer

 

Address:

4309 Hacienda Drive, Suite 150

Pleasanton,
CA 94588 Email: lkannappan@8kmiles.com

 

 

PURCHASER:

 

HEALTHCARE
TRIANGLE INC.

 

 

By:
/s/ Suresh Venkatachari

Name:
Suresh Venkatachari

Title: President

 

Address:
4309 Hacienda Drive, Suite 150

Pleasanton,
CA 94588

 

Email:
sureshv@healthcaretriangle.com

    	14 

    	 

    

EXHIBIT
A

 

COMMON
STOCK PURCHASE AGREEMENT [PURCHASER EQUITY]

    	15 

    	 

    

EXHIBIT
B

 

FORM
OF ASSIGNMENT DEED

 

 

This
Assignment Deed (Deed) is made on January 1, 2020, by 8K Miles Software Services Inc. (Assignor), a company
incorporated under the laws of Nevada, in favor of Healthcare Triangle Inc., a Nevada corporation, (Assignee).

 

WHEREAS,
on January 1, 2020, the parties above-named entered into an Asset Transfer Agreement (Agreement), whereby in connection
with the sale of the Transferred Assets (as defined in said Agreement) on a going concern, the Assignor agreed to sell, convey,
transfer and assign to the Assignee, the following, inter alia, in accordance with and subject to the terms and conditions
specified in the Agreement: Transferred Contracts, Transferred Future Contracts, Permits, Transferred Employees, Knowhow, IP,
Goodwill, Business Records, and Transferred Liabilities.

 

AND
WHEREAS, in accordance with said Agreement and for the consideration specified therein, the Assignor hereby effects such sale,
conveyance, transfer and assignment of the Transferred Contracts, Transferred Future Contracts, Permits Transferred Employees,
Knowhow, IP and Goodwill, Business Records, and Transferred Liabilities to the Assignee.

 

NOW,
THEREFORE, THIS DEED WITNESSETH AS FOLLOWS:

 

 1. By these presents, and to the extent permitted by applicable law or the underlying Permit, Transferred Contract or Transferred Future Contract, the Assignor hereby sells, transfers, conveys and assigns to the Assignee, all its right, title and interest in the Permits, Transferred Contracts and the Transferred Future Contracts, in accordance with the provisions of the Agreement, including full power to cause the Assignee’s name to be substituted for the Assignor’s name in connection therewith and to deal with the same in such manner as the Assignee deems fit.

 

 2. By these presents, the Assignor hereby sells, transfers, conveys and assigns, as applicable, to the Assignee, all its right, title and interest in and to the Knowhow, IP and Goodwill and the Business Records, in accordance with the provisions of the Agreement, including full power to cause the Assignee’s name to be substituted for the Assignor’s name in connection therewith and to deal with the same in such manner as the Assignee deems fit.

  

3.
The Assignor hereby covenants to do all such acts and things and execute all other necessary documents and depose to or
provide any declarations or oaths and render all assistance to the Assignee as may be necessary or desirable fort he Assignee
to protect, establish, vest or enforce the Assignee’s right, title and interest in respect of all or any of the
foregoing, sold, conveyed, transferred, or assigned, as the case may be, pursuant to this Deed.

 

    	17 

    	 

    

 4. The Assignor hereby undertakes to not publish, release or in any way make available to third parties any of the foregoing or any documents or other records connected therewith without the prior written consent of the Assignee, unless required to do so by law or the order of a court or governmental authority.

 

 5. The Assignor hereby confirms and covenants that on and from the date of this Deed, it does not and shall not retain any rights, title or interest in any of the foregoing or any documents or other records connected therewith, except for the right to retain one (1) photocopy thereof solely for the purposes of record keeping and ensuring compliance with the provisions of this Deed and the Agreement.

 

 6. All terms used in this Deed and not defined herein shall have the meanings specified in the Agreement.

 

 7. This Deed and all matters connected with or related to this document shall be subject to the provisions of the Agreement, which provisions are hereby incorporated into this Deed by reference.

 

 

[Signature
page follows]

 

    	18 

    	 

    

IN
WITNESS WHEREOF, the Parties have executed and delivered this Agreement effective as of the day and year first written above.

 

ASSIGNOR:

 

8K
MILES SOFTWARE SERVICES INC.

 

By:
/s/ Lakshmanan Kannappan

Name:
Lakshmanan Kannappan

Title: Chief Operating Officer

 

Address:
4309 Hacienda Drive, Suite 150

Pleasanton,
CA 94588 Email: lkannappan@8kmiles.com

 

AGREED
AND ACKNOWLEDGED:

 

ASSIGNEE:

 

HEALTHCARE
TRIANGLE INC. 

 

By:
/s/ Suresh Venkatachari

Name:
Suresh Venkatachari Title: President

 

Address:
4309 Hacienda Dr., Suite 150

Pleasanton,
CA 94588

 

Email:
sureshv@healthcaretriangle.com

    	19 

    	 

    

SCHEDULE
1.3(i)

 

TRANSFERRED
TANGIBLE ASSETS

 

Separate
List Attached.

    	20 

    	 

    

SCHEDULE
1.3 (III)

 

TRANSFERRED
CONTRACTS

 

Separate
List Attached.

    	21 

    	 

    

SCHEDULE
1.3 (IV)

 

FUTURE
TRANSFERRED CONTRACTS

 

Separate
List Attached.

    	22 

    	 

    

SCHEDULE
1.3 (V)

 

PERMITS

 

Not
Applicable.

    	23 

    	 

    

SCHEDULE
1.3 (VI)

 

TRANSFERRED
EMPLOYEES

 

Separate
List Attached.

    	24 

    	 

    

SCHEDULE
1.3 (VII)

 

KNOWHOW,
IP AND GOODWILL

 

Subject
to the provisions of the Agreement, the Knowhow, IP, and Goodwill includes the following:

 

		1.	Intellectual
                                         Properties:

 

		a.	CloudEz
                                         – Secure Cloud
                                         Solution Platform, Technology design, Product documentation and Marketing Materials

 

		b.	DataEz
                                         – Datalake Solution Platform Technology design, Product documentation and Marketing
                                         Materials

 

		2.	All
                                         knowhow connected with the operation of the Seller’s healthcare and life sciences
                                         business on or prior to the Closing Date to the extent such knowhow is under the ownership,
                                         or possession or control of the Seller.

 

		3.	All
                                         goodwill of or otherwise connected with the Seller’s healthcare and life sciences
                                         business.

    	25 

    	 

    

SCHEDULE
1.4 (VII)

 

TRANSFERRED
LIABILITIES

 

 

 

None.

    	26 

    	 

    

SCHEDULE
5.2

 

REPRESENTATIONS

 

Subject
to the provisions of the Agreement, the Seller represents to the Purchaser that subject to the provisions of the Disclosure Schedule,
each of the following statements is true, materially accurate and not misleading, and that no material information has been withheld
that would affect any Representation.

 

		1.	Organization,
                                         Authorization and Good Title

 

1.1. 
The Seller is validly existing under the laws of Nevada with full power and authority to own, transfer, sell or take on lease
its properties and to conduct its business in the manner and in the places where such properties are owned or taken on lease or
where such business is conducted by the Seller.

 

1.2. 
The Seller has the full legal right, power and all authority and approval required to enter into, execute and deliver this Agreement
and all documents connected therewith or contemplated therein (collectively, the “Transaction Documents”),
and to perform fully each of their obligations under the Transaction Documents.

 

1.3. 
The Transaction Documents do not and will not conflict with the Seller’s constituent
documents or any authorizations obtained to enter into, execute and deliver the Agreement or any other Transaction Documents or
to perform fully the Seller’s obligations under the Transaction Documents.

 

1.4. 
The execution and delivery by the Seller of the Transaction Documents and the consummation by the Seller of the transactions contemplated
therein have been validly authorized by all necessary approvals, consents, waivers, declarations, authorizations, notices and
filings, other than as contemplated under the Agreement, and except as required by the Agreement, no other approvals, consents,
waivers, declarations, authorizations from, notices to or filings with any person, trust, entity, association of persons, government
agency, or authority is necessary to authorize execution and consummation of the Transaction Documents.

 

1.5. 
The Transaction Documents have been duly executed and delivered by the Seller and are, upon such execution and delivery, valid
and binding obligations of the Seller enforceable against the Seller in accordance with their respective terms.

 

1.6. 
The Transaction Documents executed and delivered by the Seller (including any Transaction Documents to be executed and delivered
at or after Closing) will be valid and binding obligations of the Seller, enforceable in accordance with their respective terms,
and will effectively vest in the Purchaser title to, and ownership of, the Transferred Assets, including all the Transferred Tangible
Assets, Transferred

    	27 

    	 

    

Contracts,
Future Transferred Contracts, Permits, Knowhow, IP and Goodwill, and Business Records and all other rights and interests to be
transferred to the Purchaser pursuant to and as contemplated by the Transaction Documents, as contemplated under the Agreement.

 

		2.	Transferred
                                         Assets

 

2.1. 
The Transferred Assets are adequate for purposes of conducting the Seller’s healthcare and life sciences business as currently
conducted and the uses to which they are being put.

 

2.2. 
There is no pending litigation filed by or against the Seller, with respect to any ownership, leasehold or any other rights or
interests affecting the Transferred Assets, and no claim that could give rise to such litigation or proceedings has been received,
and to the Seller’s best knowledge, no such claim or litigation is threatened.

 

2.3. 
All Transferred Assets have been maintained in the ordinary course of business to meet the operational requirements of the Seller’s
healthcare and life sciences business.

 

2.4. 
The Transferred Assets are held and operated as per valid licenses, to the extent such Transferred Assets are used under license.

 

2.5. 
No government agency, instrumentality or authority has initiated any proceedings for recovery of any amounts or dues of a public
nature in respect of any Transferred Assets or any part thereof or otherwise against the Seller in connection therewith.

 

2.6. 
The Seller has not received any notices, from any governmental authorities for acquisition or public use or the grant of any rights
in respect of any Transferred Assets or any part thereof.

 

2.7. 
The Seller has not received notification that the Seller is in violation of any applicable zoning, health or other law in respect
of the Transferred Asstes, including any leased or licensed premises.

 

2.8. 
Each lease, license or other immoveable property-related Arrangement to which the Seller is a party in respect of the Seller’s
healthcare and life sciences business, is valid and enforceable against the other parties thereto, and all stamp duties and registration
charges in respect thereof have been paid. All other payments required to be made by the Seller pursuant to such agreement have
been duly paid and no material breach or default has occurred or is continuing under any such agreements.

 

2.9. 
The Seller has paid all taxes, charges, assessments, levies and similar amounts due and payable by the Seller in respect of all
premises used for the Seller’s

    	28 

    	 

    

healthcare
and life sciences business, and to the Seller’s best knowledge, no government agency, instrumentality or authority has initiated
any proceedings for recovery of land revenue, rents or other taxes and dues of a public nature in respect of such premises or
any part thereof.

 

		3.	Encumbrances
                                         and Liabilities

 

3.1. 
The Seller has not provided any letter of comfort or made any representation or given any undertaking to any person in respect
of the obligations or solvency of any person or in support of or as an inducement to or otherwise in connection with the availing
of financial assistance from any person with respect to the Transferred Assets.

 

3.2. 
The consummation of the transactions contemplated under this Agreement will not affect the operation of the Transferred Assets
or the Purchaser’s use of any utilities or otherwise breach or contravene the provisions of any agreements related to the
use of any utilities connected with the Transferred Assets.

 

		4.	Transferred
                                         Contracts

 

4.1. 
All original Transferred Contracts available with the Seller have been delivered to the Purchaser as on the Closing Date and are
valid, subsisting agreements, in full force and effect and binding upon the parties thereto and the Seller has paid in accordance
with their terms and has satisfied in full, and is not in default under any of them nor, to the Seller’s best knowledge,
is any other party to any such Transferred Contract in default thereunder.

 

4.2. 
The Seller has not received any notice of default in relation to any Transferred Contract. No condition exists that, with notice
or lapse of time or both, would constitute a default under any Transferred Contract,
such as to constitute or result in a material adverse effect on the Seller’s healthcare and life sciences business.

 

4.3. 
The Seller is not a party to or bound by or subject to any Transferred Contract affecting the Seller’s healthcare and life
sciences business, which would reasonably be expected to cause a material adverse effect on the Seller’s healthcare and
life sciences business.

 

4.4. 
The Seller has not received from a party to a Transferred Contract, any stop work order, cure notice, show cause notice or notice
of termination.

 

4.5. 
Confidential Information of third parties that has been provided to or used by the Seller in connection with the Seller’s
healthcare and life sciences business has been kept confidential and has not been disclosed to other persons except in the

    	29 

    	 

    

ordinary
course of business and then only in accordance with all duties owed to the providers of such confidential information.

 

4.6. 
The Seller has not received any notice alleging the breach of any data protection obligations applicable to the Business.

 

4.7. 
In respect of each transferable license included as part of the Transferred Contracts all license fees due thereon have been duly
paid, and all material conditions have been duly complied with and there are no grounds on which such licenses might be terminated.

 

		5.	Permits,
                                         Regulatory Compliance and Business Records

 

5.1. 
The Seller has or has applied to renew all material Permits required to carry on the Business, and each such material Permit is
valid and subsisting and has not been revoked, cancelled, terminated or lapsed.

 

5.2. 
The Seller has paid all fees due and payable in respect of all material Permits, has complied with all material conditions specified
therein, and to the Seller’s best knowledge, there are no grounds on which such authorizations, licenses, permits and approvals
might be terminated.

 

5.3. 
The Seller has materially complied with all laws applicable to the Business, including the terms of Permits, and there is no act,
omission, event or circumstance that could reasonably be expected to give rise to any action, suit, claim, demand, complaint,
hearing, investigation, demand letter, warning letter, show cause notice, or proceeding which the Purchaser could be made liable
for on account of the Seller’s healthcare and life sciences business.

 

5.4. 
The Seller has not received any notice specifying that the Seller is subject to any pending or threatened claim incurred or imposed
or based upon any provision of applicable law or regulation materially affecting the Seller’s healthcare and life sciences
business, including any environmental, health or pollution control law.

 

5.5. 
No investigation or procedures related thereto are pending with respect to any, actual or alleged material violation of any applicable
law by the Seller.

 

5.6. 
The Seller has not been suspended or debarred from doing business by any governmental authority or declared ineligible for executing
any contract with any governmental authority.

 

5.7. 
The Seller has not submitted to any governmental authority any inaccurate, untruthful, or misleading proposal, report, claim,
document or any other information.

    	30 

    	 

    

5.8. 
All records of Seller’s healthcare and life sciences business have been maintained in a consistent and complete manner and
no materials transactions or dealings have been undertaken in relation to the Seller’s healthcare and life sciences business
that are not appropriately reflected in the Seller’s records.

 

		6.	Transferred
                                         Employees

 

6.1. 
All key employees of the Seller’s healthcare and life sciences business have been identified as Transferred Employees and
named in Schedule 5: Transferred Employees to this Agreement.

 

6.2. 
The Seller has materially complied with all laws relating to employee conditions of work (including applicable standing orders),
employee benefits, and health and safety (including in relation to contract workers, to prevention of workplace sexual harassment,
and to redress of complaints, if any, in relation thereto) in respect of the Seller’s healthcare and life sciences business.

 

6.3. 
There are no recognized or other trade unions associated with the Seller or the Seller’s healthcare and life sciences business
or any part thereof.

 

6.4. 
There are no pending labor or industrial proceedings, disputes or claims connected with or affecting the Seller’s healthcare
and life sciences business and to the Seller’s best knowledge no such proceedings, disputes or claims are anticipated.

 

6.5. 
There have been no strikes, labor unrest or union negotiations affecting the Seller’s healthcare and life sciences business
as of the date hereof.

 

6.6. 
Other than as reflected in the Seller’s audited and unaudited financial statements, no amount due to or in respect of any
Transferred Employee is in arrears or unpaid, as on the dates of said statements, other than the current January 2020 month’s
salary, allowances and other benefits.

 

6.7. 
To the Seller’s best knowledge, no Transferred Employee is party to, or is otherwise bound by, any agreement or arrangement,
including any confidentiality or non-competition agreement, that adversely affects or restricts the performance of such Transferred
Employee’s duties as an employee of the Purchaser after Closing.

 

6.8. 
As on the date of this Agreement, the Seller has not received any information or notice that any Transferred Employee intends
to terminate his or her employment with the Seller after the date of the Agreement and prior to the Closing Date.

    	31 

    	 

    

		7.	Knowhow,
                                         IP and Goodwill

 

7.1. 
The Seller is authorized to sell, convey, transfer and assign the Know How, IP and Goodwill on the Closing Date in accordance
with the provisions of this Agreement.

 

7.2. 
To the Seller’s best knowledge, the Knowhow, IP and Goodwill do not violate or infringe the rights, intellectual property,
knowhow or confidential information of any third party, and there have been no acts or omissions that would prejudice the rights
of the Purchaser to enforce any Knowhow or IP, and to the Seller’s best knowledge there is no threatened or pending litigation
filed by or against the Seller, with respect thereto.

 

7.3. 
All information and communication technologies used in connection with the Seller’s healthcare and life sciences business
(“IT Systems”) are owned by, or properly licensed, leased or supplied under valid third-party licenses to the
Seller as on the date of the Agreement. The Seller is not in default under any such third-party licenses.

 

7.4. 
There are no circumstances in which the ownership, benefit, or right to use the IT Systems may be lost, or rendered liable to
termination, by virtue of the performance of this Agreement.

 

7.5. 
The IT Systems are and have been adequate for the needs of the Seller’s healthcare and life sciences business as conducted
on the date of the Agreement.

 

		8.	Insurance,
                                         Litigation and other Proceedings

 

8.1. 
The Seller has obtained and maintains insurance policies relating to the Seller’s healthcare and life sciences business
to the extent required under applicable law.

 

8.2. 
There is no civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning
letter, proceeding, investigation or request for information, pending or, to the best knowledge of the Seller, threatened with
respect to, against or affecting the Seller’s healthcare and life sciences business, or seeking to prevent or delay the
transactions contemplated in the Agreement, and no notice of any action, suit, demand, claim, complaint, hearing, investigation,
notice, demand letter, warning letter, proceeding or request for information involving or relating to any of the foregoing has
been received by the Seller.

 

8.3. 
There are no judgments, orders, injunctions, decrees, stipulations or awards (whether rendered by a court, administrative agency
or other governmental

    	32 

    	 

    

authority,
by arbitration or otherwise) against the Seller’s healthcare and life sciences business.

 

8.4. 
There is no dispute, conflict, claim or challenge relating to the Seller’s healthcare and life sciences business that is
reasonably expected to result in the creation of an Encumbrance against any of the Transferred Assets.

 

		9.	Taxation

 

9.1. 
The Seller has paid or accrued for all taxes relating to the Transferred Assets that are due and payable as of the date of this
Agreement and as of the Closing Date.

 

9.2. 
The Seller has materially complied with all applicable laws, rules and regulations concerning
the withholding and payment of taxes relating to the Transferred Assets and has timely collected or withheld and paid over
to the proper governmental authority all amounts required to be so collected or withheld and paid over, if any, for all periods
up to (but not including) the date hereof to the extent such amounts are required to be collected or withheld and paid over before
such date.

 

9.3. 
The Seller has not received any notices, demands for payment of penalties, written rulings of any tax authority or any assessment
order from any tax or governmental authority and has not entered into any settlement for payment of taxes or penalties with any
tax authority relating to the Transferred Assets or any part thereof.

 

9.4. 
To the Seller’s best knowledge, no claim has been made by an authority in a jurisdiction where the Seller does not file
tax returns that the Seller is or may be subject to taxation by that jurisdiction with respect to the Transferred Assets or any
part thereof.

 

9.5. 
There are no Encumbrances for taxes upon any assets of the Seller, which would have an effect on any of the Transferred Assets,
or the Purchaser on or after the Closing Date.

    	33 

    	 

    

EXHIBIT
C

 

DISCLOSURE
SCHEDULE

 

Disclosures
in this Disclosure Schedule are to be taken as relating to and qualifying all of the Representations, including the Representations
specifically identified in the table below. The references in the table below to Representation Paragraphs are to the paragraph
numbers in Schedule 5.2: Representations to this Agreement.

 

    	34Exhibit 10.2

HEALTHCARE
TRIANGLE, INC.

EQUITY
PURCHASE AGREEMENT

 

This
Equity Purchase Agreement (this “Agreement”) is made and entered into as of May 8, 2020 (the “Effective
Date”) between Healthcare Triangle, Inc., a Delaware corporation (the “Purchaser”) and 8K Miles Software
Services Inc., a Nevada corporation (“Seller”).

 

The
parties agree as follows:

 

 1. Sale of Equity and Consideration.

1.1 
In consideration of the Purchaser’s payment of the Purchase Price (defined below), Seller hereby sells to the Purchaser,
equity units amounting to hundred percent (100%) of the Seller’s equity interest (the “Purchased Equity”)
of Cornerstone Advisors Group, LLC, a Connecticut limited liability company (the “Company”), on the terms and
conditions set forth herein. The Purchased Equity shall have all of the rights and privileges and be subject to all of the restrictions
and obligations applicable to the Purchased Equity.

1.2 
In consideration of the Seller’s issuance of the Purchased Equity to the Purchaser, the Purchaser hereby agreed to pay the
following purchase price (collectively, the “Purchase Price”):

 

(i) 
assume the liability of the Seller to pay the
Company payments owing from Seller to the Company from time to time pursuant to the business agreements between the Seller and
the Company as mutually agreed to between the Seller and the Company (the “Assumed Liabilities”);

 

(ii) 
issue to Purchaser a Promissory Note (“Note”)
for a principal amount of $6,000,0000 less the amount of Assumed Liabilities payable at the time of repayment of the Note.

2. 
Limitations on Transfer. Purchaser shall not assign, encumber or dispose of any interest in the Purchase Equity
except to the extent permitted by, and in compliance with the provisions below and applicable securities laws.

 

2.1 
Restrictions Binding on Transferees. All transferees of the Purchased Equity or any interest therein will receive
and hold such Purchased Equity or interest subject to the provisions of this Agreement. Any sale or transfer of the Purchased
Equity shall be void unless the provisions of this Agreement are satisfied.

 

3. 
Equity Certificate Restrictive Legends. Certificates evidencing the Purchased Equity may bear such restrictive legends
as the Company and the Company’s counsel deem necessary or advisable under applicable law or pursuant to this Agreement,
including, without limitation, the following legends:

 

“THEOFFERINGANDSALEOFTHESECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED

    	1 

    	 

    

UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). ANY TRANSFER OF SUCH SECURITIES WILL BE INVALID UNLESS
A REGISTRATION STATEMENT UNDER THE SECURITIES ACT IS IN EFFECT AS TO SUCH TRANSFER OR IN THE OPINION OF COUNSEL FOR THE COMPANY
SUCH REGISTRATION IS UNNECESSARY IN ORDER FOR SUCH TRANSFER TO COMPLY WITH THE SECURITIES ACT.”

 

4.
Representations, Warranties, Covenants, and Acknowledgements of Seller.

4.1 
Organization. The Seller is a corporation duly organized and is validly existing and in good standing in the State
of Nevada.

4.2 
Authorization; Enforceability. The Seller has the full legal capacity, power to enter into and perform its obligations
under this Agreement and to consummate the transactions contemplated under this Agreement. The execution, delivery and performance
of this Agreement by the Seller and the consummation of the transactions contemplated hereby (i) have been duly authorized by
all requisite action on the part of the Seller and (ii) assuming the due authorization,
execution and delivery by the Seller and the Purchaser of this Agreement, constitutes the legal, valid and binding obligation
of the Seller, enforceable in accordance with its terms, except as limited by applicable bankruptcy, insolvency, moratorium or
other similar federal or state laws affecting the rights of creditors, and as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies.

 

4.3 
Execution and Binding Effect. This Agreement and each of the other agreements and instruments related to this Agreement
have been duly and validly executed and delivered to the Purchaser and constitute (or upon such execution and delivery will constitute)
legal, valid and binding obligations of the Seller enforceable against the Seller in accordance with their respective terms.

 

4.4 
Title to Purchased Equity. The Seller is the sole and exclusive record holder and beneficial owner of, has good
and marketable title to, and the exclusive authority to sell the Purchased Equity owned by the Seller. Upon the execution of this
Agreement, the Seller’s entire right, title and interest in and to the Purchased Equity of the Seller shall be conveyed
to the Purchaser as set forth herein.

 

4.5 
No Restraints. No statute, rule, regulation, order, decree, or injunction shall have been enacted, entered, promulgated,
or enforced by any court or governmental entity of competent jurisdiction which enjoins or prohibits the consummation of this
Agreement and shall be in effect.

 

4.6 
No Violation or Default. The execution, delivery and performance of this Agreement and the consummation of the transactions,
contemplated hereby will not result in violation, default or breach of any provision of any instrument, judgment, order, writ,
decree, contract or agreement to which the Seller is a party or by which the Seller is bound. The Seller is not in default or
breach (and, to the knowledge of the Seller, no set of facts exist that with the

    	2 

    	 

    

passage
of time or otherwise would constitute a default or breach by the Seller) under any instrument, judgment, order, writ, decree,
contract or agreement relating to the Purchased Equity of the Seller to which the Seller is a party or by which the Seller is
bound.

4.7 
Litigation. Except for a litigation filed by Keith T. Ryan against the Seller for claims for certain earnout payments
resulting from Keith T. Ryan’s sale of the Company shares to the Seller (the “Founder Dispute”), there
is no pending, threatened investigation, action or proceeding against the Seller, by or before any governmental entity or arbitrator,
and the Seller has no knowledge of any basis for any such investigation, action or proceeding. There is no pending or, to the
best of the Seller knowledge, threatened investigation, action or proceeding against any Seller by or before any governmental
entity or arbitrator which, if determined adversely to such Seller, would materially and adversely affect Seller’s ability
to consummate the transactions contemplated hereby, and has no knowledge of any basis for any such investigation, action or proceeding.

 

4.8 
Sophistication. The Seller: (a) is a sophisticated and familiar with the transactions
to those contemplated by this Agreement; (b) has the knowledge, skills and experience to evaluate the merits and risks
of the investment, value and sale of the Purchased Equity of the Seller, and with such knowledge, skills and experience, the Seller
has thoroughly evaluated the sale of the Purchased Equity, the value of the Purchased Equity and such merits and risks; and (c)
has independently and without reliance upon the Purchaser or any of their respective directors, officers, partners, members, shareholders,
affiliates or agents, and based on such information and the advice of such advisors as the Seller has deemed appropriate, made
its own analysis and decision to enter into this Agreement.

 

4.9 
Transfer for Own Account. The Seller is selling the Purchased Equity for the Seller’s own account only.

 

4.10 
No General Solicitation. At no time did the Seller present the Purchaser with or solicit the Purchaser, by means
of any publicly issued or circulated newspaper, mail, radio, television or other form of general advertising or solicitation in
connection with the offer and sale of Purchased Equity of the Seller.

 

4.11 
Advice. The Seller has been advised to consult with its own attorney and other investment and tax advisors regarding
legal, investment and tax matters concerning the Purchased Equity of the Seller and to consult with an independent tax advisor
regarding the tax consequences of selling the Purchased Equity of the Seller. The Seller is relying solely on its separate
legal, investment and tax advisors and not on any representations, warranties or statements of the Purchaser or its respective
directors, officers, partners, members, shareholders, affiliates or agents for any legal, investment or tax advice with respect
to the transactions contemplated by this Agreement.

 

4.12 
Requirements. The Seller (a) has satisfied itself as to the full observance of the laws, rules and regulations applicable
to the Seller in connection with the sale of the Purchased Equity owned by the Seller, including (i) the legal requirements of
the jurisdictions of the Seller’s incorporation for such sale, (ii) any foreign exchange management or restrictions applicable
to such sale, (iii) any governmental or other consents that may need to be obtained or

    	3 

    	 

    

filings
that need to be made, and (iv) the income tax and other tax consequences applicable to such sale, and (b) has no taxes or demands
that are payable to the tax or revenue authorities to which the Seller is subject that may cause the sale of the Purchased Equity
of the Seller to be rendered void.

 

4.13 
Continuing Rights. The Seller acknowledges that the Seller shall have no rights with respect to the Seller’s
Purchased Equity following the sale of the Seller’s Purchased Equity to the Purchaser pursuant to this Agreement.

4.14 
Tax Consequences. The Seller understands that it (and not the Purchaser) shall be responsible for its tax liability
that may arise as a result of the transactions contemplated by this Agreement. In this regard, the Seller severally and not jointly
represents and warrants to the Purchaser that: (a) Gains accruing on the sale of the Seller’s Purchased Equity shall be
income from capital gains in the Seller’s hands and shall be taxed accordingly under the tax laws of the Seller’s
tax incorporation; (b) the Seller represents and warrants that based on applicable law, no tax is to be withheld from the Purchase
Price payable to the Seller under this Agreement; and (c) the Seller’s Purchased Equity was acquired as, and is held (on
a continuous basis) till the date of transfer by the Seller as and qualify as “capital assets” (classified in the
Seller’s books of accounts under the head “investments”) within the meaning of applicable law.

 

5. 
Representations,Warranties,Covenants,andAcknowledgmentsof
Purchaser. Purchaser hereby represents, warrants, covenants, acknowledges and agrees that:

5.1 
Organization. The Purchaser is a corporation duly organized, validly existing and in good standing in the State
of Delaware.

5.2 
Power and Authority. The Purchaser has the full power and authority to own
its properties and assets, to conduct its business as presently conducted, and to execute, deliver and perform this Agreement
and all other agreements and instruments related to this Agreement.

 

5.3 
Investment. Purchaser is holding the Purchased Equity for Purchaser ’s own account, and not for the account
of any other person. Purchaser is holding the Purchased Equity for investment and not with a view to distribution or resale thereof
except in compliance with applicable laws regulating securities.

 

5.4 
Business Experience. Purchaser is capable of evaluating the merits and risks of Purchaser’s investment in
the Company evidenced by the Purchased Equity.

 

5.5 
Accredited Investor. Purchaser is an accredited investor as defined
in Rule 501 of Regulation D promulgated under the Securities Act.

 

5.6 
Access to Information. Purchaser has had the opportunity to ask questions of, and to receive answers from, the Seller
with respect to the terms and conditions of the transactions contemplated hereby and with respect to the business, affairs, financial
conditions, and results of operations of the Seller. Purchaser has had access to such financial and other information as is necessary
for Purchaser to make a fully-informed decision as to investment in the Seller by way of owning the Purchased Equity and has had
the opportunity to obtain any

    	4 

    	 

    

additional
information necessary to verify any of such information to which Purchaser has had access.

 

5.7 
Registration. Purchaser may bear the economic risk of investment for an indefinite period of time because the issuance
of the Purchased Equity to Purchaser has not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), and the Purchased Equity cannot be transferred by Purchaser unless such transfer is registered under the Securities
Act or an exemption from such registration is available. The Seller has made no agreements, covenants or undertakings whatsoever
to register the transfer of any of the Purchased Equity under the Securities Act. The Seller has made no representations, warranties,
or covenants whatsoever as to whether any exemption from the Securities Act, including, without limitation, any exemption for
limited sales in routine brokers’ transactions pursuant to Rule 144 of the Securities Act, will be available; if the exemption
under Rule 144 is available at all, it will not be available until at least one year from
issuance of the Purchased Equity and then not unless (a) a public trading market then exists in the Seller’s Purchased
Equity; (b) adequate information as to the Company’s financial and other affairs and operations is then available to the
public; and (c) all other terms and conditions of Rule 144 have been satisfied.

 

5.8 
Public Trading. None of the Seller’s securities is presently
publicly traded, and the Seller has made no representations, covenants or agreements as to whether there will be a public market
for any of its securities.

5.9 
Tax Advice. The Seller has made no warranties or representations to Purchaser with respect to the income tax consequences
of the transactions contemplated by this Agreement, and Purchaser is in no manner relying on the Seller or its representatives
for an assessment of such tax consequences.

5.10 
Market Standoff. Purchaser hereby agrees that if so requested by the Company or any representative of the underwriters
in connection with any registration of the offering of any securities of the Seller under the Securities Act, Purchaser shall
not sell, make any short sale of, loan, grant any option for the purchase of or otherwise dispose of any Purchased Equity, or
any derivative security thereof (other than those included in the registration) without the prior written consent of the Seller
or such underwriters, as the case may be, for such period of time (not to exceed 180 days) from the effective date of such registration
as the Seller or underwriters may specify. The Seller may impose stop-transfer instructions with respect to securities subject
to the foregoing restrictions until the end of such 180 day period.

 

6. 
Indemnification. Seller shall indemnify the Purchaser for any losses, claims or damages incurred or caused from
the Founder Dispute. Purchaser shall have the right to set off any amounts payable in connection with the Founder Dispute against
the payment of the amounts owing under the Note.

    	5 

    	 

    

7. 
Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware without regard to otherwise governing principles of conflicts of law. For purposes
of litigating any dispute that may arise directly or indirectly from this Agreement, the parties hereby submit and consent to
the exclusive jurisdiction of the State of California and agree that any such litigation shall be conducted only in the courts
of California or the federal courts of the United States located in California and no other courts.

 

8. 
Survival of Representations and Warranties. The representations, warranties and covenants contained in Section
3 and Section 6 shall survive the execution and delivery of this Agreement (and the issuance of the Purchased Equity).

9. 
Representation by Counsel. Purchaser hereby represents and agrees that he or she has been represented by or had
the opportunity to be represented by, independent counsel of his or her own choosing, and that he or she has had the full right
and opportunity to consult with his or her attorney(s), has carefully read and fully understands this Agreement in its entirety.
If an ambiguity or question of intent or interpretation arises, then this Agreement will be construed as if drafted jointly by
the parties to this Agreement, and no presumption or burden of proof will arise favoring or disfavoring any party to this Agreement
by virtue of the authorship of any of the provisions of this Agreement.

 

10. 
Notices. All notices and other communications related to this Agreement shall be in writing and, if not delivered
by hand, shall be mailed to the parties at such addresses set forth in the signature block of this agreement, or to the last known
address as shown on the Company’s records. Notices and communications shall be mailed by registered mail, return receipt
requested, postage prepaid. All mailings and deliveries related to this Agreement shall be deemed received only when actually
received.

11. 
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be
an original and all of which together shall be deemed to be one and the same instrument.

 

12. 
Successors and Assigns. Except as otherwise provided in this Agreement, this Agreement and the rights and obligations
of the parties hereunder, will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors,
administrators and legal representatives. The Seller and/or the Purchaser may assign
any of its rights and obligations under this Agreement.

 

13. 
No Employment Rights. This Agreement gives Purchaser no right to be retained as an employee or service provider
of the Company.

14. 
Waiver. Either party’s failure to enforce any provision or provisions of this Agreement shall not in any way
be construed as a waiver of any such provision or provisions, nor prevent that party thereafter from enforcing each and every
other provision of this Agreement. The rights granted both parties herein are cumulative and shall not constitute a waiver of
either party’s right to assert all other legal remedies available to it under the circumstances.

 

15. 
Cooperation. Purchaser agrees upon request to execute any further documents or instruments necessary or desirable
to carry out the purposes or intent of this Agreement.

    	6 

    	 

    

16. 
Headings. All headings are inserted for convenience of reference only and shall not affect the meaning or interpretation
of any such provisions or of this Agreement, taken as an entirety.

17. 
Severability. The provisions of this Agreement are severable, and, if any one or more provisions of this Agreement
is determined to be illegal, invalid or otherwise unenforceable, in whole or in part, the remaining provisions, and any partially
unenforceable provisions to the extent enforceable, shall continue in full force and effect and shall be binding and enforceable.
Upon any such determination of invalidity, the parties shall negotiate in good faith to replace the invalid provision with a valid
provision that implements the original intent of the parties as closely as possible in a mutually acceptable manner.

 

18. 
Amendment. This Agreement may not be modified, amended, altered or supplemented except by means of the execution
and delivery of a written instrument mutually executed by the Seller and Purchaser.

19. 
Complete Agreement. This Agreement constitutes the final and complete expression of all of the terms of the understanding
and agreement between the parties hereto concerning the subject matter hereof.

 

 

 

 

[Signature
page follows]

    	7 

    	 

    

IN
WITNESS WHEREOF, the parties hereto have executed this Equity Purchase Agreement as of the day and year first above written.

 

 

SELLER:

 

8K
MILES SOFTWARE SERVICES INC.,

a
Nevada Corporation.

 

By:
/s/ Lakshmanan Kannappan

Name:
Lakshmanan Kannappan

Title: Chief Operating Officer

 

Address:

4309 Hacienda Dr., Suite 150

Pleasanton,
CA 94588

 

Email: lkannappan@8kmiles.com

 

 

PURCHASER:

 

HEALTHCARE
TRIANGLE, INC.,

a
Delaware Corporation

 

By:
/s/ Suresh Venkatachari

Name:
Suresh Venkatachari

Title: Chief Executive Officer

 

Address:

4309 Hacienda Dr., Suite 150

Pleasanton,
CA 94588

 

Email:
sureshv@healthcaretriangle.com

 

 

 

 

 

 

 

 

 

 

 

HEALTHCARE
TRIANGLE – SIGNATURE PAGE TO EQUITY PURCHASE AGREEMENT

    	8 

    	 

    

SCHEDULE
A DISCLOSURE SCHEDULE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HEALTHCARE
TRIANGLE – SIGNATURE PAGE TO EQUITY PURCHASE AGREEMENT

 

    	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]